Personalis Inc. has announced the publication of new clinical study results highlighting the performance of its NeXT Personal® assay for ultrasensitive monitoring of molecular residual disease (MRD) in patients with advanced solid tumors undergoing immunotherapy. The study, published in npj Precision Oncology and led by researchers at UC San Diego Moores Cancer Center, demonstrated that the NeXT Personal test can detect circulating tumor DNA (ctDNA) at very low levels, enabling earlier identification of therapy response compared to standard imaging. Key findings include a strong correlation between ctDNA clearance and overall survival, with patients achieving molecular complete response showing seven times higher survival rates. Additionally, early molecular response was detectable a median of 23 days after starting immunotherapy, and molecular progression was identified a median of 161 days before radiographic progression. The study supports the potential of ultrasensitive ctDNA testing to inform clinical decisions across a broad range of solid tumors. The results have already been published.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260202837412) on February 02, 2026, and is solely responsible for the information contained therein.